Categories: HealthcareNews

Media Alert: Lynx.MD Leveraged for Study on Infliximab Optimization for IBD to be Presented at Crohn’s & Colitis Congress

Study real-world outcomes of IBD infliximab patients with the Anser TDM Test: Presentation by Prometheus using the Lynx GI data library

PALO ALTO, CA / ACCESSWIRE / January 17, 2024 / Lynx.MD, a provider of a comprehensive medical data intelligence platform, is honored to support our partner, Andrew Shim, Medical Affairs, Prometheus Laboratories Inc, poster presentation at the upcoming Crohn’s & Colitis Congress 2024 demonstrating the potential of therapeutic drug monitoring (TDM) to positively impact patient outcome with infliximab dose optimization.

Poster Session: Comparing Real-World Outcomes… Using TDM vs. Unoptimized Control Group

Presenter: Dr. Andrew Shim, Prometheus Laboratories Inc., University of Minnesota

When: Friday, January 26th, 7:00 PM – 8:00 PM Pacific

Venue: Bellagio, Las Vegas

Key points of interest:

  • Large-scale study conducted in real-world community-based practices.
  • TDM-guided infliximab optimization linked to reduced rates of IBD-related surgery compared to standard dosing.
  • Findings add to growing evidence supporting personalized, TDM-driven treatment for improved outcomes and reduced healthcare costs.

This study was made possible through a powerful collaboration between Prometheus Laboratories Inc. and Lynx.MD, a leading real-world medical data platform. Leveraging Lynx.MD’s rich repository of de-identified clinical data within the Lynx.MD Trusted Data Environment, Prometheus researchers gained unparalleled access to real-world treatment patterns and outcomes in a diverse patient population. This unique partnership exemplifies the power of data-driven research in advancing personalized medicine and ultimately improving patient lives.

Don’t miss this opportunity to learn more about this potentially transformative approach to IBD care at the Crohn’s & Colitis Congress. Attend Dr. Shim’s presentation to discover how data-driven insights can inform IBD treatments.

Additional Information:

Contact:
Victoria Holl
Vp of Marketing
Lynx.MD
victoria@lynx.md
650-248-4262

SOURCE: Lynx MD

View the original press release on accesswire.com

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

4 hours ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

4 hours ago